Foghorn Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Aug 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 6, 2026

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025
Collaboration revenue	$16,072	$7,557	$19,339	$13,509
Operating expenses:
Research and development	18,523	21,792	36,782	43,418
General and administrative	6,354	6,862	12,935	14,101
Total operating expenses	24,877	28,654	49,717	57,519
Loss from operations	(8,805)	(21,097)	(30,378)	(44,010)
Other income, net:
Interest income	1,609	2,309	3,351	5,001
Other income (expense), net	5	852	(39)	2,239
Total other income, net	1,614	3,161	3,312	7,240
Net loss	$(7,191)	$(17,936)	$(27,066)	$(36,770)
Net loss per share attributable to common stockholders—basic and diluted	$(0.10)	$(0.28)	$(0.39)	$(0.58)
Weighted average common shares outstanding—basic and diluted	70,629,419	62,978,219	70,087,756	62,913,804
Comprehensive loss:
Net loss	$(7,191)	$(17,936)	$(27,066)	$(36,770)
Other comprehensive loss:
Unrealized losses on marketable securities	(1)	(58)	(158)	(179)
Total other comprehensive loss	(1)	(58)	(158)	(179)
Total comprehensive loss	$(7,192)	$(17,994)	$(27,224)	$(36,949)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.